Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE) CEO Simon Morriss joins Proactive to outline the company’s investment case, its services and offerings, and a recent peer-reviewed journal publication that offered industry recognition for Genetic Technologies’ breast cancer screening technology. The Journal of Precision Medicine’s publication demonstrated the company’s technology was 9x more sensitive than current techniques, offering earlier detection and better healthcare outcomes.
Genetic Technologies’ breast screening tech 9x more sensitive than current screening
